



SHUKRA

PHARMACEUTICALS LTD.

12th August, 2023

To
The General Manager-Listing
Corporate Relationship Department
BSE Limited, Ground Floor,
P.J. Towers, Dalal Street, Mumbai.

Scrip Code: 524632

Sub: - Outcome of Meeting of Board of Directors Held on August 12, 2023

Ref: Disclosure under Regulation 30 & 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015.

Dear Sir/Madam,

With reference to above subject and in compliance with Regulation 33 and 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the outcome of the Meeting of the Board of Director held on today i.e. Saturday, August 12, 2023, has considered and approved the following: -

1. Unaudited Financial Results for the quarter ended on June 30, 2023 along with the Limited Review Report thereon.
(The copies of the aforesaid unaudited Financial Results along with the Limited Review Reports thereon are enclosed herewith.)

2. Appointment of Mrs. Sonal Gandh (DIN: 07351479) as an additional Non-Executive Independent Director of the Company w.e.f. August 12, 2023 subject to approval of shareholder of the company in the ensuing Annual General Meeting.

In compliance with SEBI Letter dated June 14, 2018 and BSE Circular LIST/COMP/14/2018-19 dated June 20, 2018, we wish to confirm that Mrs. Sonal Gandh has not been debarred from holding the office of Director by virtue of any SEBI order or any other Authority.

3. Appointment of Mrs. Rupal Patel, Practicing Company Secretary, as a Secretarial Auditor of the company.
4. Taken note on the resignation of Mr. Ashvin Trived, Non-Executive Non-Independent Director of the Company w.e.f. 12th August, 2023.
5. Reconstituted the following Committees of the Company

I. AUDIT COMMITTEE:

S.N.	Name of Committee Member	Position	Category
1	Ms. Bhoomiben Patel	Chairperson	Non-Executive -Independent Director
2	Mr. Rai Kavoorguthu Konark	Member	Non-Executive -Independent Director
3	Mrs. Sonal Gandh	Member	Non-Executive -Independent Director

CIN : L24231GJ1993PLC019079



II. NOMINATION AND REMUNERATION COMMITTEE:

S.N.	Name of Committee Member	Position	Category
1	Ms. Bhoomiben Patel	Chairperson	Non-Executive -Independent Director
2	Mr. Rai Kavoorguthu Konark	Member	Non-Executive -Independent Director
3	Mrs. Sonal Gandh	Member	Non-Executive -Independent Director

III. STAKEHOLDER RELATIONSHIP COMMITTEE:

S.N.	Name of Committee Member	Position	Category
1	Ms. Bhoomiben Patel	Chairperson	Non-Executive -Independent Director
2	Mr. Rai Kavoorguthu Konark	Member	Non-Executive -Independent Director
3	Mrs. Sonal Gandh	Member	Non-Executive -Independent Director

6. Amended the "Policy for Determination of 'Materiality' of Event/Information" to align with the requirements of the amended SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

The amended Policy for Determination of 'Materiality' of Event/Information is available on the website of the Company at <http://www.shukrapharmaceuticals.com/#>

7. Reviewed the other business of the company.

Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with circular No. CIR/CFD/ CMD/4/2015 dated 9th September, 2015 are attached as Annexure-A.

You are requested to kindly take the same on record.

The Board Meeting commenced at 03.00 P.M. and concluded at 4.30 P.M.

Thanking you,
Yours faithfully

For Shukra Pharmaceuticals Limited


Bhoomiben Patel
Director
(DIN: 08316893)



CIN : L24231GJ1993PLC019079




SHUKRA

PHARMACEUTICALS LTD.

Annexure-A

Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with circular No. CIR/CFD/ CMD/4/2015 dated 9th September, 2015 for the said appointments are as follows:

S.N.	Particulars	Details	
1.	Reason for Change Viz., Appointment, Resignation, removal, death or otherwise;	Appointment of Mrs. Sonal Gandhi (DIN -07351479) as an Additional Independent Director of the Company.	Appointment: to Comply with provision of Section 204 the Companies Act, 2013. and the Regulation 24A under SEBI (LODR) Regulations, 2015.
2.	Date and Terms of Appointment	Mrs. Sonal Deepalbhai Gandhi has been appointed as an Additional Independent Director on the Board of the Company w.e.f. 12 th August, 2023, up to the date of ensuing Annual General Meeting of the Company.	12th August, 2023 CS Rupal Patel, Practicing Company Secretary (Membership No. F6275 and COP No. 3803) as secretarial Auditor of the Company.
3.	Brief profile	Mrs. Sonal Gandhi has expertise in the filed of finance, Law and Management.	CS Rupal Patel is a Peer Reviewed Practicing Company Secretary and a Fellow Member of the Institute of Company Secretaries of India (ICSI). She is working since more than 21 (Twenty-One) Years in the field of various Corporate Laws. Her core areas of working are Companies Act, 2013, SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, The Foreign Exchange Management Act, 1999, The Goods & Service Tax, 2017 etc. Office Address: 303, Prasad Tower, Oppo. Jain Derasar Temple, Nehrunagar Char Rasta, Ahmedabad-380015. Email ID: roopalcs2001p@gmail.com
4.	Disclosure of relationships between directors (in case of Appointment of a director)	Not Applicable.	Not Applicable.



CIN : L24231GJ1993PLC019079

SHUKRA PHARMACEUTICALS LIMITED

CIN: L24231GJ1993PLC019079

3rd Floor, Dev House, Opposite WIAA Institute, Judges Bungalow Road, Bodakdev, Ahmedabad - 380 052


STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2023

		Rs. in Lakhs (Except EPS)			
Sr. No.	Particulars	QUARTER ENDED		Year Ended	
		30.06.2023 (Unaudited)	31.03.2023 (Audited)	30.06.2022 (Unaudited)	31.03.2023 (Audited)
1	Income from Operations				
I	Revenue from Operations	2,016.01	4,624.59	656.57	5,883.37
	(a) Net Sales/ Income from Operations	2,016.01	4,624.59	656.57	5,883.37
II	Other Income	63.36	89.08	0.81	119.67
	Total Income from Operations (I+II)	2,079.37	4,713.67	657.38	6,003.04
2	Expenses				
	(a) Cost of materials consumed	202.63	313.44	368.05	1,135.02
	(b) Purchase of Stock-in Trade	1,603.97	3,430.02	-	3,430.02
	(c) Changes in inventories of finished goods, and work-in-progress and stock in trade	(15.58)	209.72	32.95	(33.38)
	(d) Employee Benefit Expenses	134.45	121.03	133.73	488.92
	(e) Finance Cost	8.46	7.21	11.54	28.08
	(f) Depreciation & Amortisation Expenses	45.94	50.59	42.15	183.75
	(g) Other Expenses	56.83	185.24	26.45	326.46
	Total Expenses	2,036.70	4,317.25	614.87	5,558.87
3	Profit / (Loss) before Exceptional and Extra ordinary items and Tax (1-2)	42.67	396.42	42.51	444.17
4	Exceptional Items		-	-	-
5	Profit / (Loss) before Extra ordinary items and Tax (3-4)	42.67	396.42	42.51	444.17
6	Extra ordinary items		-	-	-
7	Net Profit / (Loss) from Ordinary Activities before Tax(5-6)	42.67	396.42	42.51	444.17
8	Tax Expenses				
	I. Current Tax	-	(3.95)	9.04	-
	II. Deferred Tax	0.64	1.92	0.68	2.72
	II. Tax of Earlier Year	-	0.80	-	0.80
	IV. MAT Credit Entitlement	-	-	-	-
9	Net Profit / (Loss) for the Period (7-8)	42.03	397.65	32.79	440.65
10	Other Comprehensive Income		(0.94)		(0.94)
	Remeasurement of defined benefit plans	-	-	-	-
	Prior Period Adjustments & Expenses				-
11	Total Comprehensive Income for the period (9+10)	42.03	396.71	32.79	439.71
12	Paid up Equity Share Capital (F. V. of Rs. 10/- Each)	716.25	391.42	156.57	391.42
13	Face Value of Equity Shares	10.00	10.00	10.00	10.00
14	Earnings per Share (of Rs. 10/- each) :				
	(a) Basic-Rs	0.59	23.46	2.09	26.21
	(b) Diluted-Rs	0.59	23.46	2.09	26.21

NOTES:

- The above Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its Meeting held on 12th August, 2023.
- The Unaudited Financial Statements are prepared in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013 ("Act") read with Companies (Indian Accounting Standards) Rules, 2015 as amended and in the format as prescribed under Regulation 33 of the SEBI (LODR) Regulations, 2015.
- The Unaudited Financial Results of the Company are available on Company's website and also on the website of BSE Limited, i.e. www.bseindia.com, where the Shares of the Company are listed.
- During the quarter ended 30th June, 2023, 1 complaints was received and 1 complaint for last quarter attended and closed.
- Previous quarter's figures have been re-grouped / re-arranged wherever necessary.
- The Company is operating in single segment, so above results are for single segment only.

Date: 12-08-2023
Place: Ahmedabad



For and on behalf of Board of Director of
SHUKRA PHARMACEUTICALS LIMITED

Bhoomiben Patel
Bhoomiben Patel
(Director)
DIN: 08316893

INDEPENDENT AUDITOR'S REVIEW REPORT on Standalone Unaudited Quarterly and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To,
The Board of Directors,
SHUKRA PHARMACEUTICALS LIMITED
Ahmedabad

1. We have reviewed the accompanying statement of unaudited standalone financial results of **SHUKRA PHARMACEUTICALS LIMITED** (the "Company"), for the quarter ended June 30, 2023 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (Ind AS) 34 on 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR MAAK and Associates
[Firm Registration No.135024W]
Chartered Accountants



CA Marmik Shah
Partner

Mem. No. 133926

UDIN : 23133926BGWEXF6132



Place : Ahmedabad
Date : 12th August, 2023